All News

2021

June

Media Release / Jun 02, 2021

Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients

Read More

May

Media Release / May 19, 2021

Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer

Read More

February

Media Release / Feb 17, 2021

Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease

Read More
2020

December

Media Release / Dec 17, 2020

Novartis builds on commitment to addressing need in neuropsychiatric disorders with Cadent Therapeutics acquisition

Read More
Media Release / Dec 09, 2020

Novartis Kisqali® data demonstrate superior benefit across main intrinsic subtypes in metastatic breast cancer

Read More
Media Release / Dec 09, 2020

Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer

Read More

September

Media Release / Sep 21, 2020

Novartis Kisqali® receives the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale

Read More

May

Media Release / May 27, 2020

Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease

Read More
Media Release / May 14, 2020

Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms

Read More
2019

December

Media Release / Dec 11, 2019

Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3

Read More

Key Releases

Ad hoc announcement pursuant to article 53 Listing Rules.

Learn More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More